Beam Therapeutics Inc (BEAM)
23.77
+2.51
(+11.81%)
USD |
NASDAQ |
May 13, 15:29
Beam Therapeutics Free Cash Flow: -169.28M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -169.28M |
| December 31, 2023 | -182.93M |
| September 30, 2023 | -391.86M |
| June 30, 2023 | -380.41M |
| March 31, 2023 | -353.49M |
| December 31, 2022 | -26.42M |
| September 30, 2022 | 39.49M |
| June 30, 2022 | 123.00M |
| March 31, 2022 | 148.21M |
| Date | Value |
|---|---|
| December 31, 2021 | -113.08M |
| September 30, 2021 | -133.96M |
| June 30, 2021 | -155.22M |
| March 31, 2021 | -131.72M |
| December 31, 2020 | -112.10M |
| September 30, 2020 | -99.64M |
| June 30, 2020 | -94.01M |
| March 31, 2020 | -86.75M |
| December 31, 2019 | -84.52M |
Free Cash Flow Range, Past 5 Years
-391.86M
Minimum
Sep 2023
148.21M
Maximum
Mar 2022
-122.48M
Average
-112.59M
Median
Free Cash Flow Benchmarks
| Eli Lilly and Co | -3.896B |
| Moderna Inc | -3.672B |
| Perspective Therapeutics Inc | -37.98M |
| Electromed Inc | 4.787M |
| Xtant Medical Holdings Inc | -10.97M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -99.75M |
| Cash from Investing (Quarterly) | -53.46M |
| Cash from Financing (Quarterly) | 2.897M |
| Free Cash Flow Per Share (Quarterly) | -1.251 |
| Free Cash Flow to Equity (Quarterly) | -102.18M |
| Free Cash Flow Yield | -8.96% |